[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338532-105":59,"doc-detail-338532-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","engineered-oncolytic-virus-expressing-b7h3-targeting-bite-enhances-antitumor-t-cell-immune-response","Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response","","Bispecific T-cell engagers (BiTEs) stimulate polyclonal T-cell immunity but B7H3-targeting BiTEs are limited by systemic toxicity. Oncolytic viruses offer a platform for locoregional delivery of therapeutic genes. This study engineered an oncolytic adenovirus encoding B7H3-targeting BiTE, aiming for persistent tumor-site expression while driving polyclonal T-cell activation and redirecting cytotoxicity toward B7H3+ tumor cells.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/engineered-oncolytic-virus-expressing-b7h3-targeting-bite-enhances-antitumor-t-cell-immune-response/338532/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/engineered-oncolytic-virus-expressing-b7h3-targeting-bite-enhances-antitumor-t-cell-immune-response/338532.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the B7H3-targeting BiTE face in current immunotherapy approaches?","Question",{"text":113,"@type":114},"The B7H3-targeting BiTE is challenged by systemic toxicity and limited exposure due to short biological half-lives.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the B7H3-targeting BiTE constructed in this study?",{"text":118,"@type":114},"A BiTE was built by linking an scFv recognizing human B7H3 to an scFv recognizing human CD3, then inserting it into an oncolytic adenovirus to form OAd-B7H3-BiTE.",{"name":120,"@type":111,"acceptedAnswer":121},"What outcomes did the study observe for T-cell activation and antitumor activity?",{"text":122,"@type":114},"OV-delivered BiTEs bound T cells and target cells, induced activation-associated cellular changes, cytokine secretion, and proliferation, and enhanced cytotoxicity against B7H3+ tumor cells, with persistent intratumoral BiTE expression in vivo.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338532,1790721389,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Open access Original research  \n Engineered oncolytic virus expressing  \nB7H3-targeting BiTE enhances antitumor T-cell immune response  \nHaoran Zhu,1 Wanrong Zhang,1 Qingguo Guo,1 Ruoyue Fan,2 Guangzuo Luo  ,2,3 Ying Liu1  \nTo cite: Zhu H, Zhang W, Guo Q, et al. Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response. Journal for ImmunoTherapy of Cancer 2024;12:e009901 . doi:10 . 1136/ jitc-2024-009901  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-009901](jitc-2024-009901)) .  \nAccepted 06 November 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \n1Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China  \n2Bionce Biotechnology, Ltd, Nanjing, China  \n3Institute of Health Science, China Medical University, Shenyang, China  \nCorrespondence to  \nDr Guangzuo Luo; [gzluo@cmu.edu.cn](gzluo@cmu.edu.cn)  \nDr Ying Liu; [liuying@cmu.edu.cn](liuying@cmu.edu.cn)  \nABSTRACT  \nBackground Bispecific T-cell engagers (BiTEs) are recombinant bispecific proteins designed to stimulate polyclonal T-cell immunity. In recent years, B7H3, a pancancer antigen, has been considered a promising target for future immunotherapy. However, the B7H3-targeting BiTE faces the challenge of systemic toxicity. Oncolytic viruses (OVs) represent a new class of cancer immunotherapeuticsand serve as an appropriate platform for locoregional delivery of therapeutic genes. In this study, we designed an oncolytic adenovirus (OAd) encoding BiTE targeting human B7H3 . We hypothesized that OVs encoding B7H3 BiTE deliver this molecule persistently to the tumor site while mediating polyclonal T-cell activation and redirecting it to tumor cells.  \nMethods B7H3-targeting BiTE was constructed by linking a single-chain variable fragment (scFv) that recognizes human B7H3 to an scFv that recognizes human CD3 . B7H3 BiTE was inserted into OAd to construct OAd-B7H3-BiTE. The function of the OV-delivered B7H3 BiTE was detected via co-culturing B7H3+ target cells and peripheral blood mononuclear cells. A humanized immune system mouse model was used to evaluate the therapeutic effects in vivo. Results B7H3 is highly expressed in a high proportion of human malignancies. OV-delivered BiTEs bind to T cells and target cells. We observed a series of phenomena reflecting T-cell activation induced by OAd-B7H3-BiTE, including cell clustering, cell size, activation markers, cytokine secretion, and proliferation. Furthermore, T-cell activation was mirrored by the corresponding cytotoxicity against B7H3+ tumor cells. In vivo, B7H3 BiTE was persistently expressed in tumors and enhanced the antitumor T-cell immune response.  \nConclusions Using an OV for the local expression of B7H3 BiTE maximizes the local concentration of BiTE while reducing systemic exposure. OV also provides a relatively “hot” T-cell immune environment for the function of BiTE. Because of its capacity to activate polyclonal T cells, BiTE has the potential to redirect virus-specific T cells to tumors. Our study provides new opportunities for the exploitation of B7H3-BiTE-armed OVs as therapeutic agents for the treatment of B7H3-positive malignancies.  \nBACKGROUND  \nA bispecific T-cell engager (BiTE) comprises two single-chain variable fragments (scFvs) that recognize a target antigen and the  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ In recent years, B7H3, as a pan-cancer antigen, has been considered a promising target for future immunotherapy. However, B7H3-targeting bispecific T-cell engagers (BiTEs) face the challenge of systemic toxicity. Recently, several research groups have attempted to combine oncolytic viruses (OVs) and BiTEs.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ OVs encoding B7H3-targeting BiTE","cbCaibBSjgWdfJRl","https://ap.wps.com/l/cbCaibBSjgWdfJRl","pdf",5066001,13,"English","# ABSTRACT\n## Background\n## Methods\n## Results\n## Conclusions\n# BACKGROUND\n## BiTE design and challenges\n# WHAT IS ALREADY KNOWN ON THIS TOPIC\n# WHAT THIS STUDY ADDS\n# HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY","[{\"question\":\"What problem does the B7H3-targeting BiTE face in current immunotherapy approaches?\",\"answer\":\"The B7H3-targeting BiTE is challenged by systemic toxicity and limited exposure due to short biological half-lives.\"},{\"question\":\"How was the B7H3-targeting BiTE constructed in this study?\",\"answer\":\"A BiTE was built by linking an scFv recognizing human B7H3 to an scFv recognizing human CD3, then inserting it into an oncolytic adenovirus to form OAd-B7H3-BiTE.\"},{\"question\":\"What outcomes did the study observe for T-cell activation and antitumor activity?\",\"answer\":\"OV-delivered BiTEs bound T cells and target cells, induced activation-associated cellular changes, cytokine secretion, and proliferation, and enhanced cytotoxicity against B7H3+ tumor cells, with persistent intratumoral BiTE expression in vivo.\"}]","Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response | PDF",1790024080,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50d33f8ca8a106683c8f5190efcf4208.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07c6909a7cb44ebacb7ef3c25567412b.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d40c9cc8c6860ccd8f3fc46e37a2a3cd.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cdb73208a0bb5fad8439bd13569e96a0.webp",980,1306]